Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2006

Conditions
PainCancerSickle Cell AnemiaSevere Burns
Interventions
DRUG

ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])

Trial Locations (28)

10467

Children's Hospital at Montefiore, The Bronx

13210

Scottish Rite Children's Medical Center, Syracuse

SUNY Upstate Medical University, Syracuse

17033

Milton S Hershey Medical Center, Hershey

19134

St. Christopher's Hospital for Children, Philadelphia

20010

Childrens National Medical Center, Washington D.C.

27710

Duke University Hospital, Durham

32207

Nemours Childrens Clinc, Jacksonville

33660

St. Joseph's Childrens Hopsital, Tampa

37232

Vanderbilt University Medical Center, Nashville

44308

Akron Children's Hospital, Akron

44501

Tod Childrens Hospital, Youngstown

52242

University Hospitals of Iowa, Iowa City

53201

Childrens Hospital of Wisconsin, Milwaukee

72202

Children's Hospital of Arkansas, Little Rock

78207

Children's Cancer and Blood Disorders Center, San Antonio

78229

Methodist Hospital, San Antonio

87131

University of New Mexico, Albuquerque

92868

Childrens Hospital of Orange, Orange

94304

Lucille Packard Childresns Hospital, Palo Alto

96826

Kapi'olani Medical Center, Honolulu

99204

Sacred Heart Medical Center, Spokane

West Virginia Univeristy, Morgantown

06106

Connecticut Childrens Medical, Hartford

07601

David Center for Childrens Pain and Palliative Care, Hackensack

08901

Cancer Institute of New Jersey, New Brunswick

B3J3G9

Iwk Health Center, Halifax

00912

San Jorge Childrens Medical, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00236093 - Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain | Biotech Hunter | Biotech Hunter